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Abstract
Aims/hypothesis We aimed to characterise the immunogenic background of insulin-dependent diabetes in a resource-poor rural
African community. The study was initiated because reports of low autoantibody prevalence and phenotypic differences from
European-origin cases with type 1 diabetes have raised doubts as to the role of autoimmunity in this and similar populations.
Methods A study of consecutive, unselected cases of recently diagnosed, insulin-dependent diabetes (n = 236, ≤35 years) and
control participants (n = 200) was carried out in the ethnic Amhara of rural North-West Ethiopia. We assessed their demographic
and socioeconomic characteristics, and measured non-fasting C-peptide, diabetes-associated autoantibodies and HLA-DRB1
alleles. Leveraging genome-wide genotyping, we performed both a principal component analysis and, given the relatively
modest sample size, a provisional genome-wide association study. Type 1 diabetes genetic risk scores were calculated to compare
their genetic background with known European type 1 diabetes determinants.
Results Patients presented with stunted growth and low BMI, and were insulin sensitive; only 15.3% had diabetes onset at
≤15 years. C-peptide levels were low but not absent. With clinical diabetes onset at ≤15, 16–25 and 26–35 years, 86.1%, 59.7%
and 50.0% were autoantibody positive, respectively. Most had autoantibodies to GAD (GADA) as a single antibody; the
prevalence of positivity for autoantibodies to IA-2 (IA-2A) and ZnT8 (ZnT8A) was low in all age groups. Principal component
analysis showed that the Amhara genomes were distinct from modern European and other African genomes.HLA-DRB1*03:01
(p = 0.0014) and HLA-DRB1*04 (p = 0.0001) were positively associated with this form of diabetes, while HLA-DRB1*15 was
protective (p < 0.0001). The mean type 1 diabetes genetic risk score (derived from European data) was higher in patients than
control participants (p = 1.60 × 10−7). Interestingly, despite the modest sample size, autoantibody-positive patients revealed
evidence of association with SNPs in the well-characterised MHC region, already known to explain half of type 1 diabetes
heritability in Europeans.
Conclusions/interpretation The majority of patients with insulin-dependent diabetes in rural North-West Ethiopia have the
immunogenetic characteristics of autoimmune type 1 diabetes. Phenotypic differences between type 1 diabetes in rural North-
West Ethiopia and the industrialised world remain unexplained.
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Abbreviations
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Introduction
Type 1 diabetes is poorly characterised in many low- and
middle-income countries of sub-Saharan Africa; specifically,
there has been uncertainty about whether its pathogenesis is
similar to the classic form of the disease found in
industrialised countries. Striking phenotypic differences from
the classic form of type 1 diabetes have been reported from
several locations in sub-Saharan Africa; these include a low
incidence in the pre-pubertal years with an age-specific peak
in the third decade [1, 2], strong associations with low socio-
economic status [3], skewing of sex ratios with male predom-
inance in some settings [4] and reported low autoantibody
prevalence, suggesting a diminished role for autoimmune
mechanisms in its aetiology compared with classic type 1
diabetes [5–7].
Classic type 1 diabetes is an autoimmune disease resulting
from the interaction between genetic susceptibility [8] and the
environment. Many loci have been shown to confer risk, of
which the HLA class II genes remain the most important.
Although the vast genetic diversity of Africa is well known
[9, 10], very little is known about how, or if, this alters the
genetic risk for type 1 diabetes in this region. Non-genetic,
environmental factors also contribute to the pathogenesis of
type 1 diabetes, their important role being inferred from the
low concordance rate for the disease in identical twins, often
less than 50% [11]. Environmental factors range from a puta-
tive role of viral infections in pancreatic beta cell death, see the
review by Op de Beeck and Eizirik [12], to nutritional factors
that may interact with genetic susceptibilities to determine
disease risk [13]. There is a significant body of experimental
evidence showing that moderate to severe, life-long undernu-
trition starting in utero affects pancreatic development and
function by, inter alia, silencing key growth and differentia-
tion factors [14–16], and by having an effect on the immune
system [17]. Ethiopia is an example of a country that has a
long history of repeated famines, and approximately 40% of
children have evidence of nutritional stunting [18]. In these
communities, undernutrition starts in utero and continues
throughout life. The widespread experience of undernutrition
in some areas of sub-Saharan Africa, taken in conjunction
with the low levels of islet-cell autoimmunity in many historic
reports from Africa [5–7], has raised the possibility that
insulin-dependent diabetes in these populations may have a
nutritional origin. Those with the lowest BMIs (15–16 kg/m2)
were said to have ‘protein-deficient pancreatic diabetes’ [19],
a type of malnutrition-related diabetes which has since been
removed from WHO classifications. So, although there is
agreement that environmental factors are important, it is not
easy to prove their aetiological significance in type 1 diabetes,
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probably because genetic factors are stable and environmental
factors change with time.
On account of uncertainties about the role of autoimmunity
in the pathogenesis of type 1 diabetes in sub-Saharan Africa,
we have carried out an immunogenetic investigation in a
consecutive, unselected cohort of newly diagnosed insulin-
dependent diabetic participants from a community in
Ethiopia. The genetic objectives were to investigate the
genome-wide underpinnings of type 1 diabetes and the lead-
ing European type 1 diabetes risk loci in this population. The
study was carried out in a rural community, the Amhara of
North-West Ethiopia, whose socioeconomic conditions are
typical of many regions in sub-Saharan Africa.
Methods
Setting
The study was based in Gondar, Ethiopia, a university city
750 km north-west of the capital, Addis Ababa. Gondar has
a central university hospital and ten stable satellite/peripheral
health centres, which provide care for all patients with diabe-
tes in a predominantly rural health zone comprising 2.6
million people. In order for the study to be representative of
both the rural and urban populations, the region chosen had to
have a stable healthcare infrastructure that was inclusive of the
90% of the population who live in rural areas. The entire
diabetes service in this region has been developed and over-
seen by the same consultant physician for more than 30 years;
thus, diagnosis and treatment at both rural and urban clinics
have been carried out under the oversight of the same clinical
team with the same treatment and management plan.
Epidemiological studies of the diabetes care and outcomes
in this region have been extensively described [1, 4, 20].
Participants
Patients were entered sequentially into this study without
selection bias. All patients and control participants were from
the Amhara, the second-largest ethnic group in Ethiopia
(approximately 29% of the total Ethiopian population); their
language is Amharic, a Semitic language in the Afroasian
group of languages [21] and, phenotypically, the Amhara
have many Caucasoid features. This report includes data from
patients aged up to 35 years with insulin-requiring diabetes
and attending the University of Gondar Diabetes and
Paediatric Clinics and associated rural clinics. All patients
presented with a high plasma glucose and a degree of meta-
bolic decompensation; all complained of weight loss (or
parents worried about a very sick child), polydipsia and poly-
uria; most of the children and a high percentage of adults
(50%) were ketoacidotic at presentation. All patients included
in the study required insulin treatment continuously from first
presentation. Control participants were hospital attendees
selected in the same manner as previously [3]; eligibility
criteria for control participants included no history of diabetes,
normal random plasma glucose, aged up to 35 years and
belonging to the Amhara ethnic group. Control samples were
used only for autoantibody, HLA and genome investigations.
Clinical characterisation
After metabolic stabilisation, a questionnaire was verbally
administered in Amharic to record details of the duration and
treatment of their diabetes, and details of their education, occu-
pation and socioeconomic circumstances; height and weight
were measured as previously described [3]. BMI was calculat-
ed as weight (kg) divided by height squared (m2). Age and sex-
adjusted height and BMI z scores were derived using WHO
Anthro software (version 3.2.2; https://www.who.int/
growthref/tools/en/; accessed 15 June 2019) [22]. Whole
body bioimpedance was measured using a Bodystat meter
(Bodystat, Douglas, Isle of Man) and fat mass was calculated
by the method of Kotler et al [23]. Venous blood samples for
study purposes were obtained at a median of 2.5 months (IQR
1–7) from diagnosis using vacutainers, and plasma separation
was carried out on site; samples were stored at −70°C, initially
in Gondar and subsequently in the UK.
Laboratory analyses
Autoantibodies to GAD (GADA), IA-2 (IA-2A) and ZnT8
(ZnT8A) were measured by radiobinding assays as previously
described [24, 25]. All samples found to be GADA-positive
using full-length GAD65 were re-assayed using truncated
GAD65(96–585) radiolabel [26]; whereas 17 (8.5%) control
participants were positive for GADA in the full-length GAD
assay, the number were reduced to four (2.0%) in the truncat-
ed GAD assay. As only 6 of 137 patients found positive for
GADA with full-length GAD were negative in the truncated
GADA assay, results for truncated GAD65(96–585) were used
in subsequent analyses. C-peptide was measured by Roche
‘ECLIA’ C-peptide chemiluminescence assay on a Cobas
8000 E602 machine (Switzerland), with a minimal detection
limit of 0.010 μg/l.
Genotyping and quality control
After extraction of DNA, patients and control participants
were genotyped on the Infinium OmniExpress Exome
Beadchip platform (Illumina, San Diego, CA, USA) at the
Children’s Hospital of Philadelphia Center for Applied
Genomics (Philadelphia, PA, USA). Quality control was
performed using PLINK (v.1.90Beta4.5) [27], excluding indi-
viduals with discordant sex information, duplicate individuals
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and individuals with missing genotype >5%. SNPs with a call
rate <95%, minor allele frequency <1% and Hardy–Weinberg
equilibrium p < 10−5 were removed (708,143 SNPs
remained).
HLADR selected genotypes were measured by the method
of Bunce et al [28]; due to the remaining limited volume of
extracted DNA, 188 of 236 patients and 152 of 200 control
participants were HLA typed.
We carried out a genome-wide association study (GWAS),
a genetic risk score (GRS) analysis for type 1 diabetes and
principal component (PC) analyses: details are in the
Statistical analysis section (below).
Statistical analysis
Anthropometric, metabolic, autoantibody and HLA statuses
of patients were tested by t tests or ANOVA for continuously
distributed variables (using log transformation where appro-
priate) or by χ2 tests for discrete variables. A p value of <0.05
was considered to be statistically significant.
GWAS was carried out using a univariate linear mixed
model within GEMMA (https://github.com/genetics-
statistics/GEMMA v. 0.94) [29], which accounts for
population stratification and relatedness using the Wald test.
Additionally, 55 established type 1 diabetes-implicated
signals and their proxy SNPs were tested (11,748 SNPs)
[30], and 403 established type 2 diabetes-implicated variants
and their proxy SNPs were also tested (24,926 SNPs) [31].
Proxy SNPs were found using raggr (http://raggr.usc.edu, v. 3.
5.0, accessed 26 July 2018), with a linkage disequilibrium
threshold of r2 < 0.8 in the European and African
populations. The association tests were also performed in a
restricted set of cases positive for at least one autoantibody.
GRS for type 1 diabetes was calculated using PLINK by
multiplying the number of risk-increasing alleles by the natu-
ral log of the OR at each locus and summing the OR across
risk loci for each individual. Included were 19 SNPs (electron-
ic supplementary material [ESM] Table 1) in the GRS, using
weights as previously described [32]. The distribution of the
type 1 diabetes GRS was compared for all diabetes cases vs
control participants and for autoantibody-positive cases using
linear regression, adjusting for sex and the first four PCs.
PC analysis was performed using PLINK as follows: the
1000 Genomes [33] and Ethiopian genotype files were
merged, removing 4277 SNPs with location conflicts. SNPs
with a minor allele frequency <0.01 were removed, and link-
age disequilibrium pruning was performed at r2 < 0.2 between
any two SNPs. Also removed was one individual from each
pair with an identity-by-descent value >0.3 (46 individuals
removed). PLINK was then used to calculate PCs and R
(v.3.5.0) was used to plot the first three PCs.
Ethical approval
The study was approved by the institutional ethics review
boards of Gondar College of Medicine and Health Sciences
Table 1 Metabolic characteristics and autoantibody status at presentation of Ethiopian patients with type 1 diabetes
Characteristic Age at onset (year) p value
0–15 16–25 26–35 All
Number tested 36 124 76 236
Male, n (%) 16 (44.4) 90 (72.6) 59 (77.6) 165 (69.9) 0.001
Blood glucose at diagnosis, mmol/l, median (IQR) 29.3 (27.1–33.3) 29.7 (24.0–33.3) 26.1 (20.4–32.2) 28.3 (22.2–33.3) 0.03
Insulin dose after stabilisation, U/kg/day, mean (SD) 0.92 (0.37) 0.79 (0.23) 0.66 (0.18) 0.77 (0.26) <0.001
Diabetes duration, months, median (IQR) 3 (1–7) 2 (1–6) 2 (1–7) 2.5 (1–7) NS
C-peptide, μg/l, median (IQR) 0.46 (0.32–1.09) 0.77 (0.33–1.35) 0.98 (0.46–1.87) 0.80 (0.34–1.42) 0.03
Height, SD z score, mean (SD)a −1.49 (1.09) −1.18 (0.91) −1.09 (0.83) −1.20 (0.92) NS
BMI, SD z score, mean (SD)a −1.20 (1.14) −1.44 (1.11) −0.97 (1.16) −1.25 (1.15) 0.02
% body fat, mean (SD) 6.2 (8.7) 11.9 (7.7) 13.7 (6.5) <0.001
Rural birth, n (%) 30 (83.3) 115 (92.7) 66 (86.8) 211 (89.4) NS
Autoantibody prevalence, n (%)b
GADAc 29 (80.6) 69 (55.6) 33 (43.4) 131 (55.5) 0.001
IA-2A 1 (2.8) 5 (4.0) 2 (2.6) 8 (3.4) NS
ZnT8A 6 (16.7) 11 (8.9) 7 (9.2) 24 (10.2) NS
Any antibody present 31 (86.1) 74 (59.7) 38 (50.0) 143 (60.6) 0.001
a Based on WHO standards, see Methods
bNote: Non-diabetic controls, n = 200: positive for autoantibodies, GADA, n = 4; IA-2A, n = 2; ZnT8A, n = 5; any antibody, n = 11
cGADA, antibodies against truncated GAD, i.e. GAD65(96–585)
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and the UK National Research Ethics Services Committee
(REC; reference: 14/WA/0132). Written, informed consent
was obtained from all participants or their parents, as
appropriate.
Results
The characteristics of the diabetes cases are shown in Table 1;
results for antibody positivity in control participants are
shown separately below the patient results. Patients were
investigated at a median of 2.5 months after clinical diagnosis.
The overwhelming majority (89.4%) of the participants were
born in rural areas around Gondar, Ethiopia. The median age
at diagnosis was 21 years; only 36 (15.3%) were diagnosed at
15 years of age or younger, and most cases were in the 16–
25 year age group. There was a striking male preponderance,
but only in the post-pubertal age groups: 72.6% in the 16–
25 year age group and 77.6% in the 26–35 year age group.
The mean BMI SD z scores were lower than WHO norms in
all age groups; in the adult groups, the BMIs (mean [SD])
were equivalent to 18.6 (2.4) and 19.8 (2.9) kg/m2 in the
16–25 and 26–35 year age groups, respectively. The percent-
age of body fat was also low in all age groups. All cases had
low, but detectable, non-fasting C-peptide levels. The insulin
treatment doses were <1 U/kg/day for all age groups. Of the
236 cases, 112 (47.5%) reported that their families’ source of
income was subsistence farming or labouring, while only 41
(17.4%) had paid employment or owned businesses.
Educational levels were low, with only 74 of the 200 adults
(37%) reporting completed secondary education (not shown).
Autoantibody status
Table 1 shows that 86.1% of cases in the 0–15 year age group,
59.7% of cases in the 16–25 year age group and 50.0% of
cases in the 26–35 year age group were autoantibody positive.
GADA was the most common autoantibody and the most
common when there was a single autoantibody; thus, 114 of
143 autoantibody-positive cases had GADA as the only auto-
antibody. Of control participants, 2% were GADA positive.
The prevalence of GADA declined from 80.6% in those aged
≤15 years to 55.6% in the 16–25 year age group and 43.4% in
the 26–35 year age group. In contrast, the prevalence rates of
ZnT8A and IA-2A were low, even in those with childhood
onset, without any age-specific trend. The GADA-positive
and GADA-negative groups were further compared (ESM
Table 2). In comparison with the autoantibody (GADA)-posi-
tive group, the negative (GADA) group were slightly older
(23.6 vs 20.4 years, p < 0.001), had lower plasma glucose at
presentation (26.7 vs 29.8 mmol/l, p = 0.01), had higher C-
peptide levels (0.96 vs 0.71 μg/l, p = 0.015) and had lower
insulin requirements (0.72 vs 0.81 U/kg, p = 0.012). They
had similar BMIs (SD z score −1.25, or 19.3 kg/m2 [mean
for both]). Percentage body fat was not significantly different
in the two groups: GADA negative, 12.7% vs GADA posi-
tive, 10.8%; p = 0.065.
Genomic analysis
PC analysis PC analysis is a technique that identifies the major
axes of variation in genetic data. Leveraging the genome-wide
genotyping data, the first PCs were plotted against the 1000
Genomes reference set [33] to visualise the relationship of the
Ethiopian samples against worldwide super-populations (Fig.
1a, b). Comparing PC1 with PC2 (Fig. 1a), a clear separation
was observed of the Ethiopian sample from the 1000
Genomes groups, and plotting PC2 vs PC3 (Fig. 1b) revealed
clearly that the sample from the Amhara of Ethiopia was
distinct from European and other African populations.
HLA analysis HLA-DRB1*03:01 was positively associated
with diabetes (81/188, 43.1%) compared with control partici-
pants (40/152, 26.3%; OR 2.12; p = 0.0014), and this associ-
ation persisted when considering only GADA-positive cases
(54/102, 52.9%) (Table 2). HLA-DRB1*04 was also positive-
ly associated with diabetes (83/188, 44.1%) vs control partic-
ipants (37/152, 24.3%; OR 2.46; p = 0.0001); this association
persisted when GADA-positive cases only were considered
(51/102, 50.0%). HLA-DRB1*15 was strongly protective in
the total diabetes group (7/188, 3.7%) compared with control
participants (25/152, 16.4%; OR 0.20; p < 0.0001); this asso-
ciation persisted when GADA-positive cases only were
considered (2/102, 2.0%). In GADA-negative cases, these
three HLA disease associations were less striking (HLA-
DRB1*03:01 [31.4%, p = 0.40]), but, importantly, with signif-
icant risk with HLA-DRB1*04 (37.2%, p = 0.035) and signif-
icant protection with HLA-DRB1*15 (5.8%, p = 0.018).
GRSGRS for type 1 diabetes is shown in Fig. 2, and the type 1
diabetes-associated SNPs used in the GRS analysis are shown
in ESM Table 1.
The average type 1 diabetes GRS was significantly higher
for diabetes cases than for control participants. The mean
(SD), compared with that of the control participants of 0.154
(0.067), was 0.189 (0.064) for the total diabetes group, 0.199
(0.067) for the autoantibody-positive group and 0.171 (0.057)
for the autoantibody-negative group, with p = 1.6 × 10−7, p =
1.54 × 10−9 and p =NS, respectively.
GWAS (ESM Figs 1, 2, 3, Table 3; ESMTables 3, 4) No single
SNP achieved genome-wide significance (p < 5 × 10−8) when
all diabetic participants were investigated as a single group,
irrespective of autoantibody positivity (ESM Figs 1 and 2).
However, despite the modest sample size, SNPs within the
HLA region were border-line GWAS significant (p < 5 ×
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10−6) for autoantibody-positive patients (Table 3, ESM Fig.
2), with the strongest signal falling in the HLA-DQB1 locus
(rs9273363, p = 5.13 × 10−8; Table 3). We also observed
suggestively associated signals on chromosomes 4, 16 and 3
(Table 3). The GWAS analysis did not show genomic infla-
tion (λ = 1.01; ESM Fig. 3). We then took a candidate SNP
approach and extracted all type 1 and type 2 diabetes-
associated SNPs; the strongest type 1 diabetes-associated
signal was in the HLA-DQB1 region (rs1063355, p = 6.28 ×
10−6) (ESM Table 3); however, no type 2 diabetes-associated
loci achieved significance (ESM Table 4).
Discussion
This detailed study of consecutive, unselected, newly diag-
nosed patients in an impoverished, mainly rural population
in sub-Saharan Africa shows that the majority have low C-
Fig. 1 PC analysis. (a) The first
two PCs (PCs 1 and 2). (b) The
second and third PCs (PCs 2 and
3). These are based on genome-
wide genotypes of the Ethiopian
(Amhara) participants compared
with 1000 Genomes ancestral
groups. AFR, African; AMR,
Americas. EAS, East Asian. ETP,
Ethiopian; EUR, European; SAS,
Southeast Asian
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peptide levels and low BMI, as well as diabetes-associated
autoantibodies and diabetes risk alleles for type 1 diabetes; a
smaller group are autoantibody negative and have someminor
differences in their profile. As with previous studies in this and
other locations in the region, the cases have a different disease
phenotype; thus, the median age of onset is later than that
observed in most industrialised countries and there is a strik-
ing male predominance in the post-pubertal age groups.
Autoantibody prevalence
The prevalence of diabetes-related autoantibodies was high,
falling from 86.1% in the youngest age group to 50.0% in the
oldest group. This autoantibody frequency and age depen-
dence were similar to [34, 35], if slightly lower [36] than,
some other reports from industrialised countries, with all
demonstrating lower prevalence of autoantibody positivity
with increasing age of onset. However, whereas the majority
of type 1 diabetes patients in industrialised countries have
multiple diabetes-related autoantibodies, in this present
Ethiopian study most had GADA alone, which was evident
even in the 0–15 age group. Of note, the prevalence of auto-
antibodies to full-length GAD was relatively high in control
participants, at 8.5% (mentioned in Methods section); howev-
er, in contrast to cases, the majority of these autoantibodies
were directed to the low-risk N-terminal epitope [26]. The
prevalence of other autoantibodies, IA-2A and ZnT8A, was
low in all age groups, including those with childhood-onset
disease. Our findings contrast with two urban studies from
Ethiopia that found much lower levels of GADA, albeit with
very low or absent IA-2A; however, these participants were
studied 6 or more years after diagnosis [7, 37]. Unfortunately,
comparisons in sub-Saharan Africa are difficult because there
are very few studies where blood sampling for autoantibody
status has taken place close to the time of diagnosis and
involved both urban and rural populations, with the rural
population forming the majority in most countries in this
region. Moreover, the vast genetic diversity in this continent
also complicates comparisons [9, 10, 38]. A recent study of
type 1 diabetes fromWest Africa (Cameroon) investigated an
urban group shortly after clinical diagnosis and compared
them with a Belgian population. As in Ethiopia, few (9%)
had childhood-onset type 1 diabetes, and in those who were
classified as having type 1 diabetes a very low percentage of
children (≤15 years) and adults (median age 30 years) were
autoantibody positive; the majority of these had GADA, and
far fewer had IA-2A or ZnT8A [2]: the overall autoantibody
prevalence in those classified as having type 1 diabetes was
lower than in the Amhara. The adult Belgian diabetic partici-
pants had a much higher incidence of multiple autoantibodies
than the Cameroonian participants. The West Africans of
Cameroon are of Bantu background and belong to a different
genomic group to the Amhara [9, 10, 38]. These findings of
different autoantibody profiles among ethnic groups are
echoed by studies in South Africa comparing the profiles of
type 1 diabetes in black (mixed ethnicity) and white partici-
pants. Interestingly, the peak age of clinical onset was later in
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Fig. 2 Box and whisker plot showing GRS for type 1 diabetes. The GRS
was calculated using 19 established type 1 diabetes-associated SNPs of
European background; variants, risk alleles and weights are listed in ESM
Table 1 (see the Methods/Statistical analysis section for details). Diabetic
patients were compared with control participants: autoantibody-positive
cases (AA+) (n = 121, vs controls, p = 1.54 × 10−9), all cases (n = 187, vs
controls, p = 1.6 × 10−7), autoantibody-negative cases (AA−) (n = 66, vs
controls, p = NS) and control participants (n = 137). The vertical lines
denote the maximum and minimum values
Table 2 Analysis of the frequency of the three most prominent type 1 diabetes risk alleles in European-origin populations among Ethiopian patients
with diabetes and non-diabetic controls
Allele Patients with diabetes, n (%) Controls
n = 152
All diabetes vs controls GADA-positive diabetes vs
controls
GADA-negative diabetes vs
controls
All
n = 188
GADA
positive
n = 102
GADA
negative
n = 86
OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
DRB1*03:01 81 (43.1) 54 (52.9) 27 (31.4) 40 (26.3) 2.12 (1.34–3.37) 0.0014 3.15 (1.85–5.35) <0.0001 1.38 (0.78–2.44) 0.40
DRB1*04 83 (44.1) 51 (50.0) 32 (37.2) 37 (24.3) 2.46 (1.54–3.93) 0.0001 3.11 (1.82–5.32) <0.0001 1.84 (1.04–3.27) 0.035
DRB1*15 7 (3.7) 2 (2.0) 5 (5.8) 25 (16.4) 0.20 (0.08–0.47) <0.0001 0.10 (0.02–0.43) 0.0001 1.31 (0.12–0.85) 0.018
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black compared with white participants, and both groups were
heavier than the Amhara (average BMI for black and white
participants, 24.0 kg/m2 and 22.4 kg/m2, respectively). When
studied several years after clinical diagnosis (mean duration
>5 years), overall GADA positivity was 60% and 66% for
black and white participants, respectively; IA-2A positivity
was lower in the former than the latter (19% vs 41%, respec-
tively), especially in those aged >21 years at diagnosis (7.3%
vs 33%, respectively) [39]. Taken together with our data, these
results [2, 39] from three different regions of sub-Saharan
Africa suggest that there is considerable heterogeneity in the
prevalence of autoantibody profiles both within Africa and
betweenAfrican and European populations. These differences
appear to be independent of the age of onset of diabetes and,
for the present, remain unexplained.
Genomic analysis
Using genome-wide genotyping data, our study population
was shown to be distinct from European and other African
ancestral groups; based on what is known of their demograph-
ic and linguistic history, this was not unexpected [10]. GWAS
and HLA analysis confirmed the predominant HLA associa-
tion with type 1 diabetes-associated risk and protective alleles.
By contrast, and of note, no associations were found for type 2
diabetes-associated loci. However, our sample size was low
and power limited, and therefore the results should be seen as
relatively preliminary. In view of the autoantibody and HLA
results a GRS was applied, based on SNPs associated with
type 1 diabetes on a European genetic background. This was
done with the knowledge that the results might not be as
robust when applied to a different ethnic group [40]. Despite
the European background of the SNPs employed, the
Ethiopian diabetes group showed a significantly increased
GRS compared with control participants, mainly associated
with autoantibody-positive cases. In addition, these Amhara
diabetes patients showed an association with HLA class II
alleles HLA-DRB1*03:01 and HLA-DRB1*04, in both the
total diabetes cohort as well as in those with GADA, while
HLA-DRB1*15 was strongly protective for diabetes. GADA-
negative patients demonstrated an association with HLA-
DRB1*04 and protection with HLA-DRB1*15. In short, they
have some of the immunogenic features of the autoimmune
diabetes of adolescent and adult European-origin and Chinese
populations [41], while the diabetes-associated autoantibody,
GADA, was similarly the dominant autoantibody and associ-
ated with HLA-DRB1*03:01, consistent with heterogeneity of
type 1 diabetes endotypes [42, 43]. Our observations imply a
widespread commonality in GADA-dominant, HLA-
associated adult-onset autoimmune diabetes, despite global
variation in the precise HLA-associated genotypes.
Moreover, as with adult-onset autoimmune diabetes in
Europe and China, both IA-2A and ZnT8A had lower
frequencies and, in the present Amhara cohort, even in
childhood-onset type 1 diabetes the prevalence of IA-2A
was very low.
Implications
Given that the majority of patients with diabetes in this rural
Ethiopian population appear to have an autoimmune basis to
their diabetes, the results do not support the hypothesis previ-
ously suggested by ourselves and others [1, 19] that the
disease could have a direct relationship to undernutrition
during prenatal and early postnatal life. Although type 1
diabetes is strongly associated with low socioeconomic status
and skeletal disproportion in this community [3], it remains
unclear whether nutrition or related aspects of poverty influ-
ence disease development and contribute to the relatively late
peak age of onset of their diabetes. Of note, communities with
diverse ethnic backgrounds in sub-Saharan Africa, but with-
out (reported) malnutrition, have found a later peak age
Table 3 GWAS: border-line genome-wide significant signals associated with autoantibody-positive diabetes cases (p < 5 × 10−6)
SNP Chromosome Positiona Minor/major allele MAFb in cases MAF in controls OR CI p Locus
rs9273363 6 32626272 A/C 0.445 0.217 1.281 1.226–1.339 5.13 × 10−8 HLA-DQB1
rs2760985 6 32566398 A/G 0.261 0.088 1.363 1.288–1.443 1.16 × 10−7 HLA-DRB1
rs9268528 6 32383108 G/A 0.407 0.358 1.261 1.208–1.316 1.57 × 10−7 BTNL2
rs9268542 6 32384721 G/A 0.407 0.365 1.256 1.203–1.312 3.23 × 10−7 BTNL2
rs11947273 4 92544404 T/C 0.336 0.445 0.811 0.778–0.846 1.25 × 10−6 CCSER1
rs2187818 6 32395568 G/T 0.360 0.427 0.805 0.770–0.841 1.48 × 10−6 HLA-DRA
rs9268585 6 32397403 T/G 0.360 0.427 0.805 0.770–0.841 1.48 × 10−6 HLA-DRA
rs4784939 16 58468211 T/C 0.309 0.146 1.280 1.216–1.347 2.43 × 10−6 GINS3
rs996482 3 20583674 T/C 0.318 0.172 0.817 0.782–0.853 4.06 × 10−6 SGOL1
a Base pair position reported for genome build 37
bMAF, minor allele frequency. Note that minor allele is the effect allele
Statistics: Linear mixed model with Wald test in GEMMA
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incidence [2, 39]. One line of evidence does, however, point to
the involvement of a complex gene–environment interaction
affecting the age of disease onset. Ethiopian Jews moved in
large numbers from rural areas around Gondar to urban areas
of Israel in the 1980s and 1990s. After immigration to Israel
the age of onset of type 1 diabetes in the young offspring of
these Ethiopian emigres slowly fell (in those with at least two
high-risk alleles for diabetes), in proportion to the time that
their Ethiopian-born parents had been resident in Israel; at the
same time the incidence of type 1 diabetes in these young
people rose dramatically, to be one of the highest within the
Jewish communities of Israel [44].
Another unexplained phenotypic feature in our study was
the marked male preponderance in the post-pubertal but not
pre-pubertal age groups; this is not a feature of type 2 diabetes
in Ethiopia [4]. A less marked post-pubertal male preponder-
ance in type 1 diabetes has been noted previously in European
cohorts [45, 46]. The cause of this striking sex bias is not clear,
but may include sex-related immune and differential epige-
nome effects [17, 47].
Limitations of the study
There is wide genetic diversity in sub-Saharan Africa; that
being the case, we have studied a single ethnic group to limit
genetic diversity within this study and have emphasised that
the results from the Semitic-background Amhara differ in
autoantibody profi le from the Bantu-background
Cameroonians [2], who were investigated at a similar time,
close to clinical diagnosis. Additionally, both the Amhara and
Bantu have shown some differences from European back-
ground groups. Our results, therefore, are not fully
generalisable, neither when confined to sub-Saharan Africa
nor on a more global basis. However, the differences associ-
ated with genetic diversity can be used as a tool to help throw
light on the relationships between genetic background and
autoantibody profile in type 1 diabetes.
In summary, the majority of insulin-dependent diabetes in
the Amhara of North-West Ethiopia is autoimmune in nature,
and the genetic risk and protective factors for type 1 diabetes
are largely common to those found in Europeans with type 1
diabetes. The results of this study and reports from other areas
of sub-Saharan Africa highlight the need for a wider under-
standing of the gene–environment interactions giving rise to
differences in timing of peak incidence, male preponderance
(in those with post-pubertal onset) and autoantibody profile in
type 1 diabetes.
Acknowledgements The authors thank C. Self, research student, for
assistance with computing and M. McDonnell and A. Magill,
Department of Clinical Biochemistry, Royal Victoria Hospital, Belfast
for laboratory support. We are grateful to V. Lampasona, San Raffaele
Scientific Institute, Milan and A. Lernmark, LundUniversity, Sweden for
the plasmids used for islet autoantibody measurement.
Data availability The datasets generated during the current study are
available by application to the corresponding author on reasonable
request.
Funding DIWP and ERT received a grant from the Association of
Physicians of Great Britain and Ireland; DLC is supported by a grant from
the NIH, NIH1K99HD099330-01; SFAG is supported by the NIH (RO1
DK085212) and the Daniel B. Burke Endowed Chair for Diabetes
Research; STJ and RDL are funded by Type 1 Diabetes UK (DUK 19/
0005951); RDL is funded by the EFSD (MMBP1C3R), the EU (EU-
FP7:282510) and St Bartholomew’s Hospital, London, Charity
(OGA011582); TV is funded by the British Diabetic Twin Trust.
Authors’ relationships and activities The authors declare that there are
no relationships or activities that might bias, or be perceived to bias, their
work.
Contribution statement SAB, AGD, AG and AH identified patients and
control participants, were responsible for measuring and recording demo-
graphic data, and oversaw the procurement and initial storage of patient
samples. RM, DLC, KMH, BFV, KL, SS and SFAGwere responsible for
designing, measuring and analysis of genetic assays. RM and DLC, BFV
and KL, were also involved in manuscript preparation. TV carried out
data analysis. STJ performed genetic and data analysis. RDL was respon-
sible for genetic design and analysis, and manuscript preparation. AJKW
and HFW were responsible for autoantibody assay design and analysis.
DIWP and ERT were responsible for conception, design, data collection,
data analysis andmanuscript preparation. All co-authors were involved in
drafting and/or revising the article and have approved the final version of
the manuscript. ERT is responsible for the integrity of the work as a
whole.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References
1. Balcha SA, Phillips DIW, Trimble ER (2018) Type 1 diabetes in a
resource-poor setting: malnutrition related, malnutrition modified,
or just diabetes? Curr Diab Rep 18:47. https://doi.org/10.1007/
s11892-018-1003-7
2. Asanghanwa M, Gorus FK, Weets I et al (2014) Clinical and
biological characteristics of diabetic patients under age 40 in
Cameroon: relation to autoantibody status and comparison with
Belgian patients. Diabetes Res Clin Pract 103:97–105. https://doi.
org/10.1016/j.diabres.2013.11.013
3. Fekadu S, YigzawM, Alemu S et al (2010) Insulin-requiring diabe-
tes in Ethiopia: associations with poverty, early undernutrition and
anthropometric disproportion. Eur J Clin Nutr 64:1192–1198.
https://doi.org/10.1038/ejcn.2010.143
Diabetologia
4. Alemu S, Dessie A, Seid E et al (2009) Insulin-requiring diabetes in
rural Ethiopia: should we reopen the case for malnutrition-related
diabetes? Diabetologia 52:1842–1845. https://doi.org/10.1007/
s00125-009-1433-5
5. Panz VR, Kalk WJ, Zouvanis M, Joffe BI (2000) Distribution of
autoantibodies to glutamic acid decarboxylase across the spectrum
of diabetes mellitus seen in South Africa. Diabet Med 17:524–527.
https://doi.org/10.1046/j.1464-5491.2000.00324.x
6. Lutale JJK, ThordarsonH, Holm PI, Eide GE, Vetvik K (2007) Islet
cell autoantibodies in African patients with type 1 and type 2 diabe-
tes in Dar es Salaam Tanzania: a cross sectional study. J
Autoimmune Dis 4:4. https://doi.org/10.1186/1740-2557-4-4
7. Siraj ES, Gupta MK, Yifter H et al (2016) Islet-cell associated
autoantibodies in Ethiopians with diabetes mellitus. J Diabetes
Complications 30:1039–1042. https://doi.org/10.1016/j.jdiacomp.
2016.05.005
8. Barrett JC, Clayton D, Concannon P et al (2009) Genome-wide
association study and meta-analysis finds over 40 loci affect the
risk of type 1 diabetes. Nat Genet 41:703–707. https://doi.org/10.
1038/ng.381
9. CampbellMC, Tishkoff SA (2008) African genetic diversity: impli-
cations for human demographic history, modern human origins,
and complex disease mapping. Annu Rev Genomics Hum Genet
9:403–433. https://doi.org/10.1146/annurev.genom.9.081307.
164258
10. Gurdasani D, Carstensen T, Tekola-Ayele F et al (2015) The
African Genome Variation Project shapes medical genetics in
Africa. Nature 517:327–332. https://doi.org/10.1038/nature13997
11. Redondo MJ, Yu L, Hawa M et al (2001) Heterogeneity of type 1
diabetes: analysis of monozygotic twins in Great Britain and the
United States. Diabetologia 44:354–362. https://doi.org/10.1007/
s001250051626
12. Op de Beeck A, Eizirik DL (2016) Viral infections in type 1 diabe-
tes mellitus—why the β cells? Nat Rev Endocrinol 12:263–273.
https://doi.org/10.1038/nrendo.2016.30
13. Carlsson A, Kockum I, Lindblad B et al (2012) Low risk HLA-DQ
and increased body mass index in newly diagnosed type 1 diabetes
children in the Better Diabetes Diagnosis study in Sweden. Int J
Obes 36:718–724. https://doi.org/10.1038/ijo.2011.122
14. Waterland RA, Lin JR, Smith CA, Jirtle RL (2006) Post-weaning
diet affects genomic imprinting at the insulin-like growth factor 2
(Igf2) locus. Hum Mol Genet 15:705–716. https://doi.org/10.1093/
hmg/ddi484
15. Park JH, Stoffers DA, Nicholls RD, Simmons RA (2008)
Development of type 2 diabetes following intrauterine growth
retardation in rats is associated with progressive epigenetic silenc-
ing of Pdx1. J Clin Invest 118:2316–2324. https://doi.org/10.1172/
JCI33655
16. Sandovici I, Smith NH, Nitert MD et al (2011) Maternal diet and
aging alter the epigenetic control of a promoter–enhancer interac-
tion at the HNF4α gene in rat pancreatic islets. Proc Natl Acad Sci
U S A 108:5449–5454
17. Moore SE, Cole TJ, Collinson AC, Poskitt EM, McGregor IA,
Prentice AM (1999) Prenatal or early postnatal events predict infec-
tious deaths in young adulthood in rural Africa. Int J Epidemiol 28:
1088–1095. https://doi.org/10.1093/ije/28.6.1088
18. Amare ZY, Endris M, Mehari AB (2019) Determinants of nutri-
tional status among children under age 5 in Ethiopia: further anal-
ysis of the 2016 Ethiopia demographic and health survey. Glob
Health 15:62. https://doi.org/10.1186/s12992-019-0505-7
19. Abdulkadir J, Mengesha B, Welde Gebriel Z et al (1990) The clin-
ical and hormonal (C-peptide and glucagon) profile and liability to
ketoacidosis during nutritional rehabilitation in Ethiopian patients
with malnutrition-related diabetes mellitus. Diabetologia 33:222–
227
20. Alemu S, Dessie A, Tsegaw A et al (2015) Retinopathy in type 1
diabetes: major differences between rural and urban dwellers in
northwest Ethiopia. Diabetes Res Clin Pract 109:191–198. https://
doi.org/10.1016/j.diabres.2015.04.010
21. Fort M, de Stefano G-F, Cambon-Thomsen A et al (1998) HLA
class II allele and haplotype frequencies in Ethiopian Amhara and
Oromo populations. Tissue Antigens 51:327–336. https://doi.org/
10.1111/j.1399-0039.1998.tb02971.x
22. WHO Geneva (2009) WHO AnthroPlus software for personal
computers. Available from www.who.int/growthref/tools/en/;
accessed 15 Jun 2019
23. Kotler DP, Burastero S,Wang J, Pierson RN Jr (1996) Prediction of
body cell mass, fat-free mass, and total body water with bioelectri-
cal impedance analysis: effects of race, sex and disease. Am J Clin
Nutr 64:489S–497S. https://doi.org/10.1093/ajcn/64.3.489S
24. Bonifacio E, Yu L, Williams AK et al (2010) Harmonization of
glutamic acid decarboxylase and islet antigen-2 autoantibody
assays for National Institute of Diabetes and Digestive and
Kidney Diseases consortia. J Clin Endocrinol Metab 95:3360–
3367. https://doi.org/10.1210/jc.2010-0293
25. Long AE, Gillespie KM, Rokni S, Bingley PJ, Williams AJK
(2012) Rising incidence of type 1 diabetes is associated with altered
immunophenotype at diagnosis. Diabetes 61:683–686. https://doi.
org/10.2337/db11-0962
26. Williams AJK, Lampasona V,Wyatt R et al (2015) Reactivity to N-
terminally truncated GAD65(96–585) identifies GAD autoanti-
bodies that are more closely associated with diabetes progression
in relatives of patients with type 1 diabetes. Diabetes 64:3247–
3252. https://doi.org/10.2337/db14-1694
27. Purcell S, Neale B, Todd-Brown K et al (2007) PLINK: a tool set
for whole-genome association and population-based linkage analy-
ses. Am J Hum Genet 81:559–575. https://doi.org/10.1086/519795
28. Bunce M, O’Neill CM, Barnardo MC et al (1995) Phototyping:
comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3,
DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing
sequence-specific primers (PCR-SSP). Tissue Antigens 46:355–
367. https://doi.org/10.1111/j.1399-0039.1995.tb03127.x
29. Zhou X, Stephens M (2012) Genome-wide efficient mixed-model
analysis for association studies. Nat Genet 44:821–824. https://doi.
org/10.1038/ng.2310
30. Mishra R, Chesi A, Cousminer DL et al (2017) Relative contribu-
tion of type 1 and type 2 diabetes loci to the genetic etiology of
adult-onset, non-insulin-requiring autoimmune diabetes. BMC
Med 15(1):88. https://doi.org/10.1186/s12916-017-0846-0
31. Mahajan A, Taliun D, Thurner M et al (2018) Fine-mapping of an
expanded set of type 2 diabetes loci to single-variant resolution
using high-density imputation and islet-specific epigenome maps.
Nat Genet 50:1505–1513. https://doi.org/10.1038/s41588-018-
0241-6
32. OramRA, Patel K, Hill A et al (2016) A type 1 diabetes genetic risk
score can aid discrimination between type 1 and type 2 diabetes in
young adults. Diabetes Care 39:337–344. https://doi.org/10.2337/
dc15-1111
33. Clarke L, Fairley S, Zheng-Bradley X et al (2017) The International
Genome Sample Resource (IGSR): a worldwide collection of
genome variation incorporating the 1000 Genomes project data.
Nucleic Acids Res 45:D854–D859. https://doi.org/10.1093/nar/
gkw829
34. Wang J, Miao D, Babu S et al (2007) Prevalence of autoantibody
negative diabetes is not rare at all ages and increases with older age
and obesity. J Clin Endocrinol Metab 92:88–92. https://doi.org/10.
1210/jc.2006-1494
35. Kim CS, Song MK, Park JS et al (2007) The clinical and immuno-
genetic characteristics of adult-onset type 1 diabetes mellitus in
Korea. Acta Diabetol 44:45–54. https://doi.org/10.1007/s00592-
007-0241-y
Diabetologia
36. Bravis V, Kaur A, Walkey HC et al (2018) Relationship between
islet autoantibody status and the clinical characteristics of children
and adults with incident type 1 diabetes in a UK cohort. BMJ Open
8:e020904. https://doi.org/10.1136/bmjopen-2017-020904
37. Gill GV, Tekle A, Reja A et al (2011) Immunological and C-
peptide studies of patients with diabetes in northern Ethiopia: exis-
tence of an unusual subgroup possibly related to malnutrition.
Diabetologia 54:51–57. https://doi.org/10.1007/s00125-010-1921-
7
38. Fan S, Kelly DE, Beltrame MH et al (2019) African evolutionary
history inferred from whole genome sequence data of 44 indige-
nous African populations. Genome Biol 20:82. https://doi.org/10.
1186/s13059-019-1679-2
39. Padoa CJ, Rheeder P, Pirie FJ, Motala AA, van Dyk JC, Crowther
NJ (2019) Identification of a subgroup of black South Africans with
type 1 diabetes who are older at diagnosis but have lower levels of
glutamic acid decarboxylase and islet antigen 2 autoantibodies.
Diabet Med. https://doi.org/10.1111/dme.14204
40. Perry DJ, Wasserfall CH, Oram RA et al (2018) Application of a
genetic risk score to racially diverse type 1 diabetes populations
demonstrates the need for diversity in risk-modeling. Sci Rep 8:
4529. https://doi.org/10.1038/s41598-018-22574-5
41. Zhu M, Xu K, Chen Y et al (2019) Identification of novel T1D risk
loci and their association with age and islet function at diagnosis in
autoantibody-positive T1D individuals: based on a two-stage
genome-wide association study. Diabetes Care 42:1414–1421.
https://doi.org/10.2337/dc18-2023
42. Leslie RD, Grant SFA (2018) The dynamic origins of type 1 diabe-
tes. Diabetes Care 41:2441–2443. https://doi.org/10.2337/dci18-
0034
43. Battaglia M, Ahmed S, Anderson MS et al (2020) Introducing the
endotype concept to address the challenge of disease heterogeneity
in type 1 diabetes. Diabetes Care 43:5–12. https://doi.org/10.2337/
dc19-0880
44. Zung A, Elizur M, Weintrob N et al (2004) Type 1 diabetes in
Jewish Ethiopian immigrants to Israel: HLA class II immunogenet-
ics and contribution of new environment. Hum Immunol 65:1463–
1468. https://doi.org/10.1016/j.humimm.2004.09.006
45. Pundziute-Lycka A, Dahlquist G, Nystrom L et al (2002) The inci-
dence of type 1 diabetes has not increased but shifted to a younger
age at diagnosis in the 0–34 years group in Sweden 1983–1998.
Diabetologia 45:784–791
46. Kyvik KO, Nystrom L, Gorus F et al (2004) The epidemiology of
type 1 diabetes mellitus is not the same in young adults as in chil-
dren. Diabetologia 47:377–384. https://doi.org/10.1007/s00125-
004-1331-9
47. Khulan B, Cooper WN, Skinner BM et al (2012) Periconceptual
maternal micronutrient supplementation is associated with wide-
spread gender related changes in the epigenome: a study of a unique
resource in the Gambia. Hum Mol Genet 21:2086–2101. https://
doi.org/10.1093/hmg/dds026
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Affiliations
Shitaye A. Balcha1 & Abayneh G. Demisse2 & Rajashree Mishra3,4,5 & Tanwi Vartak6 & Diana L. Cousminer3,5,7 &
Kenyaita M. Hodge3,5 & Benjamin F. Voight7,8 & Kim Lorenz7,8 & Stanley Schwartz9 & Samuel T. Jerram6 &Arla Gamper10 &
Alice Holmes11 & Hannah F. Wilson12 & Alistair J. K. Williams12 & Struan F. A. Grant3,5,7,13,14 & R. David Leslie6 &
David I. W. Phillips15 & Elisabeth R. Trimble16
1 Department of Internal Medicine, Gondar University Hospital,
Gondar, Ethiopia
2 Department of Pediatrics and Child Health, School of Medicine,
University of Gondar, Gondar, Ethiopia
3 Division of Human Genetics, The Children’s Hospital of
Philadelphia, Philadelphia, PA, USA
4 Graduate Group in Genomics and Computational Biology, Perelman
School of Medicine, University of Pennsylvania, Philadelphia, PA,
USA
5 Center for Spatial and Functional Genomics, The Children’s
Hospital of Philadelphia, Philadelphia, PA, USA
6 Blizard Institute, Queen Mary University of London, London, UK
7 Department of Genetics, Perelman School of Medicine, University
of Pennsylvania, Philadelphia, PA, USA
8 Department of Systems Pharmacology and Translational
Therapeutics, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA
9 Main Line Health System, Wynnewood, PA, USA
10 Severn Postgraduate School of Primary Care, Health Education
England, Bristol, UK
11 Avon and Wiltshire Mental Health Partnership NHS Trust,
Clevedon, UK
12 Diabetes and Metabolism, Translational Health Sciences,
University of Bristol, Southmead Hospital, Bristol, UK
13 Institute for Diabetes, Obesity andMetabolism, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA, USA
14 Department of Pediatrics, Perelman School of Medicine, University
of Pennsylvania, Philadelphia, PA, USA
15 MRC Lifecourse Epidemiology Unit, University of Southampton,
Southampton General Hospital, Southampton, UK
16 Centre for Public Health, Institute of Clinical Science, Queen’s
University Belfast, Grosvenor Road, Belfast BT12 6BA, UK
Diabetologia
